News | May 25, 2021
Bal Pharma launches BALflu, Favipiravir formulation in India
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
The product is indicated for the chronic management of patients with Urea Cycle Disorders
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Acquisition strengthens EY’s Veeva Centers of Excellence, expanding clinical, regulatory, and commercial services for global pharma and biotech companies
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
Subscribe To Our Newsletter & Stay Updated
